Patient info Open main menu

Glycopyrronium Bromide 0.2 mg/ml solution for injection glycopyrronium bromide – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
0.2 mg/ml (200 microgram/ml)
Contains active substance:

Patient leaflet - Glycopyrronium Bromide 0.2 mg/ml solution for injection

1. What Glycopyrronium Injection is and what it is used for

Glycopyrronium bromide belongs to a group of medicines called anticholinergic drugs. Glycopyrrolate Injection may be used

  • to protect against some of the unwanted effects of drugs such as neostigmine or pyridostigmine, which are used to reverse the effects of certain types of muscle- relaxing drugs (called non-depolarising muscle relaxants)
  • before an operation, to reduce saliva and other secretions and to make the stomach contents less acid
  • before or during an operation, to reduce or prevent slowness of the heartbeat during surgery.

2. What you need to know before you use Glycopyrronium Injection

You must not be given Glycopyrronium Injection

  • if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine (listed in section 6).
  • if you have glaucoma (increased pressure in the eye).
  • if you suffer from myasthenia gravis (a disorder that causes extreme muscle weakness and fatigue).
  • if you have an enlarged prostate.
  • if you have stomach or bowel problems such as obstruction of the stomach (pyloric stenosis) or bowel causing vomiting, abdominal pain and swelling (paralytic ileus).
  • if you are taking Anticholinesterase-antimuscarinic combinations such as neostigmine plus glycopyrronium should be avoided in patients with a prolonged QT interval (irregular heart rhythm).

Warnings and precautions

Talk to your doctor or nurse before you are given Glycopyrronium Injection

  • if you have Down’s Syndrome.
  • if you are over 60 years of age.
  • if you are a child.
  • if you have history of heart disease, heart attack, coronary heart disease or irregular heartbeats or high blood pressure.
  • if you have a condition characterised by rapid heartbeat (including over-active thyroid, heart failure or heart surgery).
  • if you have gastric reflux (a condition in which the liquid stomach contents backs up (regurgitates) into the gullet.
  • if you have diarrhea.
  • if you have ulcerative colitis (an inflammation of the large intestine).
  • if you have kidney disease you need to avoid repeated or large doses.
  • if you have an overactive thyroid gland.
  • if you have a high temperature (fever) (as the drug will inhibit sweating).
  • if you have been administered inhalation anesthesia (to put you asleep before an operation) as it may cause a change in your normal heart rhythm.
  • if you are pregnant or are breast feeding (see section Pregnancy and breast-feeding below

Other medicines and Glycopyrronium Injection

Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines.

A number of drugs can interact with Glycopyrronium Injection which can significantly alter their effects. These drugs include:

  • Drugs for depression known as Tricyclic Antidepressants (for example amitriptyline or imipramine) and Monoamine Oxidase Inhibitors (MAOIs) (for example phenelzine, tranylcypramine).
  • Clozapine which is used to treat severe mental disorders.
  • Strong pain relievers such as Nefopam
  • Amantadine, levodopa which is used to treat Parkinson's disease or viral infection.
  • Phenothiazines used to treat severe mental problems or nausea, vomiting or vertigo (for example chlorpromazine, fluphenazine,

    prochlorperazine, trifluoperazine).

    • Antihistamines used to treat allergies (for example promethazine).
    • Pethidine (used to treat moderate to severe pain).
    • Domperidone or metoclopramide (used to treat nausea and vomiting).
    • Ketoconazole (used to treat fungal infections).
    • Memantine (used to treat Alzheimer’s disease).
    • Parasympathomimetics (these are drugs that affect chemicals in the body which are involved in transmission of nerve impulses to a muscle) (for example carbachol, neostigmine, physostigmine).
    • Ritodrine (used to prevent uncomplicated premature labour).
    • Corticosteroids used to treat various conditions including asthma and inflammatory disease (for example prednisolone).
    • Slow-dissolving digoxin tablets, disopyramide (used to treat heart problems).

Glyceryl trinitrate tablets (used to treat angina) may not dissolve under the tongue as well as usual owing to the dry mouth which glycopyrronium bromide causes.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.

Driving and using machines

Glycopyrrolate may cause your eyesight to become blurred and this could interfere with your ability to drive or operate machinery safely. You should not drive or use machines after being given this medicine until the doctor advises you that you are safe to do so.

Information on sodium content

This medicine contains less than 1 mmol (23 mg) sodium per ml, that is to say essentially ‘sodium- free’.

3. How to use Glycopyrronium Injection

The recommended dose is:

Dosage when used before an operation

Adults and elderly

200 to 400 micrograms (0.2 to 0.4mg) may be injected into a vein or into a muscle before the anaesthetic is given. Alternatively, a dose of 4 to 5 micrograms per kilogram of body weight (0.004 to 0.005mg per kg) may be used, up to a maximum dose of 400 micrograms (0.4mg).

Use in children and adolescents:

4 to 8 micrograms per kilogram of body weight (0.004 to 0.008mg per kg) up to a maximum of 200 micrograms (0.2mg) may be injected into a vein or into a muscle before the anaesthetic is given.

Dosage when used during an operation

Adults and elderly

A single dose of 200 to 400 micrograms (0.2 to 0.4mg) should be given by injection into a vein. Alternatively, a single dose of 4 to 5 micrograms per kilogram of body weight (0.004 to 0.005mg per kg) may be used, up to a maximum of 400 micrograms (0.4mg). This dose may be repeated if necessary.

Use in children and adolescents

A single dose of 200 micrograms (0.2mg) should be given by injection into a vein. Alternatively, a single dose of 4 to 8 micrograms per kilogram of body weight (0.004 to 0.008mg per kg) may be used, up to a maximum of 200 micrograms (0.2mg). This dose may be repeated if necessary.

Dosage when reversing the effects of non-depolarising muscle relaxants

Adults and elderly:

200 micrograms (0.2mg) per 1,000 micrograms (1mg) of neostigmine or the equivalent dose of pyridostigmine, by injection into a vein. Alternatively, a dose of 10 to 15 micrograms per kilogram of body weight (0.01 to 0.015mg per kg) may be injected into a vein with 50 micrograms per kg (0.05mg per kg) of neostigmine or equivalent dose of pyridostigmine. Glycopyrrolate Injection may be administered at the same time and from the same syringe with the neostigmine or pyridostigmine.

Use in children and adolescents

10 micrograms per kg of body weight (0.01mg per kg) may be injected into a vein with 50 micrograms per kg (0.05mg per kg) of neostigmine or the equivalent dose of pyridostigmine. Glycopyrrolate Injection may be administered at the same time and from the same syringe with the neostigmine or pyridostigmine.

Method of administration:

Glycopyrronium Injection is administered by injection into a vein or muscle.

Your doctor will decide the correct dose for you depending on your circumstances. Your dose may be calculated according to your weight. The injection may need to be repeated depending on your response.

Product : Glycopyrronium Bromide 0.2 mg/ml Solution for Injection

Dimension (mm) :

240 x 400 mm

Franklin Gothic Book - 10 pt

Version : V3Date : Sept 2024
Sequence Number : 0003

Back

If you have been given more Glycopyrronium Injection than you should

This is unlikely because the dose will be administered by a health professional.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines this medicine can cause side-effects, although not everybody gets them.

Consult a doctor straight away if you notice any of the following symptoms - you may need urgent medical treatment:

Swelling mainly of the face, lips or throat which makes it difficult to swallow or breathe, itching and rashes. This could be a sign of a severe allergic reaction or angioedema (frequency not known, cannot be estimated from the available data).

All medicines can cause allergic reactions although serious allergic reactions are very rare. Other side effects have also been reported under the following frequency

Very rare (may affect up to 1 in 10,000 people)

glaucoma (increased pressure in the eyes).

Not known (frequency cannot be estimated from the available data) • a dry mouth

  • difficulty in passing water (urinating)
  • blurred vision or reduced ability to sweat
  • a faster heart rate than normal
  • palpitations (an awareness of strong, thumping heartbeats) • difficulty in passing stools (constipation)
  • reduced lung secretion
  • fear of bright light
  • redness and dryness of the skin
  • confusion
  • feeling unwell
  • vomiting
  • feeling giddy
  • feeling sick (nausea)
  • unable to completely empty the bladder. (urinary retention) • urgent need to urinate
  • slow heart rate followed by rapid heart rate, palpitations and irregular heartbeat.

If any of the side effects become serious, or you notice any side effects not listed in this leaflet, please tell your doctor.

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme.

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Glycopyrronium Injection

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

If only part used, discard the remaining solution.

Do not use this medicine if you notice the ampoule is damaged or if the contents are discoloured.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Glycopyrronium Injection contains

The active substance is glycopyrronium bromide

The other ingredients are sodium chloride, hydrochloric acid, water for injection

What Glycopyrronium Injection looks like and contents of the pack

Clear, colourless solution

Glass ampoules: 10 x 1 ml

Marketing Authorisation Holder

Novumgen Limited

20-22 Wenlock Road, London, N1 7GU,

United Kingdom

Manufacturer

EQL Pharma AB

Stortorget 1

222 23 Lund

Sweden

This leaflet was last revised in Oct 2024

Product : Glycopyrronium Bromide 0.2 mg/ml Solution for Injection

Dimension (mm) :

240 x 400 mm

Franklin Gothic Book - 10 pt

Version : V3Date : Sept 2024
Sequence Number : 0003

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 55863/0107

Last revision stated in the text: October 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Glycopyrronium Bromide 0.2 mg/ml solution for injection

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Glycopyrronium bromide
Strength 0.2 mg/ml (200 microgram/ml)
Pharmaceutical form Solution for injection
Clear, colourless, sterile solution.
How is it taken Intravenous, Intramuscular
Excipients Sodium Chloride, Hydrochloric Acid, Water for injection
Pack sizes 10 ampoule
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Chemical and physical in-use stability has been demonstrated for 48 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Storage This medicinal product does not require any special storage conditions.
For storage conditions after dilution of the medicinal product, see section 6.3.
Drug group (ATC) Quaternary ammonium antimuscarinic
  1. A Alimentary tract and metabolism drugs
    1. A03 Drugs for functional gastrointestinal disorders
      1. A03A Drugs for functional gastrointestinal disorders
        1. A03AB Synthetic anticholinergics, quaternary ammonium compounds for functional gastrointestinal disorders
          1. A03AB02 glycopyrronium bromide
Marketing authorisation PL 55863/0107 (first authorised 12 July 2024)
Marketing authorisation holder Novumgen Limited
Codes GTIN 5065014037768 · BNF 15010300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.